p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases

被引:1041
作者
Kumar, S [1 ]
Boehm, J [1 ]
Lee, JC [1 ]
机构
[1] GlaxoSmithKline, Pharmaceut Res & Dev, King Of Prussia, PA 19406 USA
关键词
D O I
10.1038/nrd1177
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The p38 MAP kinases are a family of serine/threonine protein kinases that play important roles in cellular responses to external stress signals. Since their identification about 10 years ago, much has been learned of the activation and regulation of the p38 MAP kinase pathways. Inhibitors of two members of the p38 family have been shown to have anti-inflammatory effects in preclinical disease models, primarily through the inhibition of the expression of inflammatory mediators. Several promising compounds have also progressed to clinical trials. In this review, we provide an overview of the role of p38 MAP kinases in stress-activated pathways and the progress towards clinical development of p38 MAP kinase inhibitors in the treatment of inflammatory diseases.
引用
收藏
页码:717 / 726
页数:10
相关论文
共 77 条
  • [1] Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity
    Adams, JL
    Boehm, JC
    Gallagher, TF
    Kassis, S
    Webb, EF
    Hall, R
    Sorenson, M
    Garigipati, R
    Griswold, DE
    Lee, JC
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (21) : 2867 - 2870
  • [2] Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
    Adams, JL
    Boehm, JC
    Kassis, S
    Gorycki, PD
    Webb, EF
    Hall, R
    Sorenson, M
    Lee, JC
    Ayrton, A
    Griswold, DE
    Gallagher, TF
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) : 3111 - 3116
  • [3] Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079-6468(08)70091-2
  • [4] Deficiency of the stress kinase p38α results in embryonic lethality:: Characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells
    Allen, M
    Svensson, L
    Roach, M
    Hambor, J
    McNeish, J
    Gabel, CA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (05) : 859 - 869
  • [5] Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
  • [6] Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO
  • [7] 2-S
  • [8] Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures
    Badger, AM
    Roshak, AK
    Cook, MN
    Newman-Tarr, TM
    Swift, BA
    Carlson, K
    Connor, JR
    Lee, JC
    Gowen, M
    Lark, MW
    Kumar, S
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2000, 8 (06) : 434 - 443
  • [9] Barone FC, 2001, J PHARMACOL EXP THER, V296, P312
  • [10] Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction
    Behr, TM
    Nerurkar, SS
    Nelson, AH
    Coatney, RW
    Woods, TN
    Sulpizio, A
    Chandra, S
    Brooks, DP
    Kumar, S
    Lee, JC
    Ohlstein, EH
    Angermann, CE
    Adams, JL
    Sisko, J
    Sackner-Bernstein, JD
    Willette, RN
    [J]. CIRCULATION, 2001, 104 (11) : 1292 - 1298